Q-omics provides the consensus-scored DNM1P46 profile across patient tissues and cancer cell-line models. DNM1P46 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DNM1P46 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DNM1P46 RNA expression shows 18,558 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where DNM1P46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNM1P46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNM1P46 survival associations across molecular data types. DNM1P46 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNM1P46 RNA expression–survival associations across cancer types. High DNM1P46 expression shows unfavorable associations in ACC, LGG and STAD, but favorable associations in UVM, KIRC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for DNM1P46 RNA expression.
This table summarizes DNM1P46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DNM1P46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNM1P46 shows lower tumor expression in THCA, BLCA, LUAD, LUSC and UCEC and higher tumor expression in KIRC. The KIRC box plot shows higher DNM1P46 RNA expression in tumor versus normal tissue (log2 FC = +0.385, t-test p < 0.001).
This table shows molecular features associated with DNM1P46 in patient tissues and cancer cell lines. In patient samples, DNM1P46 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNM1P46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD.
